Drug Trial Radar · NCT00175019
Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010
Last checked: Nov 20, 2026Latest source record: Jul 27, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,086
Actual
Start
Jul 2003
Primary completion
Feb 2007
Study completion Feb 2007
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Sep 15, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the long-term safety of febuxostat, once daily (QD), compared to allopurinol in reducing serum urate levels in subjects with gout.
Conditions
- Gout
Interventions
FebuxostatDrug
Febuxostat 80 mg, tablets, orally, once daily.
FebuxostatDrug
Febuxostat 120 mg, tablets, orally, once daily.
AllopurinolDrug
Allopurinol 100 mg or 300 mg, tablets, orally, once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 1.Time frame: Month 1
- Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 12.Time frame: Month 12
- Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 24.Time frame: Month 24
- Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 36.Time frame: Month 36
- Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Last Visit on Treatment.Time frame: Last Visit on treatment (up to 40 months).
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.